Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G for ASCENDIS PHARMA A/S - ADR ADR (ASND).
- Disclosed ownership: 5%.
- Date of event: 31 Mar 2025.
T. Rowe Price Investment Management, Inc. - 31 Mar 2025 SCHEDULE 13G Report for ASCENDIS PHARMA A/S - ADR ADR (ASND)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Security
- ASCENDIS PHARMA A/S - ADR ADR
- Symbol
- ASND
- Shares outstanding
- 61,076,480 shares
- Disclosed Ownership
- 3,053,824 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G
- Filing time
- 14 May 2025, 10:47:09 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 5% ownership in ASCENDIS PHARMA A/S - ADR ADR (ASND) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 May 2025, 10:47.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 5% | 3,053,824 | 3,048,618 | 0 | Ellen York | Vice President |